Oklo (OKLO) Stock Tumbles as Analysts Cut Targets and Insiders Offload $170M

Key Takeaways

Table of Contents

B. Riley reduced Oklo’s price target to $92 from $129 while maintaining its Buy recommendation
Craig-Hallum dropped its target to $71 from $87 with a Hold rating, pointing to escalating capital requirements
Needham slashed its target from $135 down to $73 while keeping its Buy rating, suggesting approximately 20% potential upside
CEO Jacob Dewitte and CFO Richard Bealmear each offloaded approximately 72,000 shares at $60 per share on March 13; company insiders have sold roughly $170M in stock over the last 90 days
In positive developments, Oklo’s Atomic Alchemy division secured both a DOE Nuclear Safety Design Agreement and an NRC materials license

Oklo’s stock performance has been turbulent over the past six months. The nuclear energy startup, currently trading around $60.76, has declined 42% during this timeframe and sits significantly below its 52-week peak of $193.84.

Oklo Inc., OKLO

Multiple Wall Street firms revised their price projections downward this week after the company released its Q4 2025 financial results. While targets decreased, most analysts maintain their overall positive outlook — they’re simply adjusting expectations.

B. Riley reduced its price objective from $129 to $92 while maintaining its Buy recommendation. The firm highlighted tangible business developments: DOE authorization for the Aurora facility at Idaho National Laboratory, a prepayment deal with Meta for as much as 1.2 gigawatts in Ohio, early-stage fuel facility construction, and regulatory achievements for its Atomic Alchemy isotope division.

Needham also maintained its Buy rating but significantly lowered its target from $135 to $73. This revised target still suggests roughly 20% upside potential from present levels, and Wall Street’s consensus target hovers around $94.80 with a “Moderate Buy” rating.

Craig-Hallum took a more conservative stance. The firm retained a Hold rating while cutting its target from $87 to $71. The firm adjusted its projections to reflect higher operational expenses, elevated capital expenditures, and revised timing assumptions regarding future funding requirements. It also excluded anticipated 2026 isotope revenue — likely under $5 million — from its financial model pending additional information.

Growing Capital Requirements and Insider Transactions Dampen Confidence

Oklo concluded Q4 2025 with $1.4 billion in cash reserves. Following the quarter’s end, the company secured another $1.2 billion in funding. For 2026, management projected operating cash consumption of $80 million to $100 million, combined with investing cash use of $350 million to $450 million.

Despite its cash position, the company recorded an EBITDA loss of $97 million across the trailing twelve months and a full-year 2025 operating loss of $139.3 million. Wall Street analysts don’t anticipate profitability during the current year.

Compounding concerns, CEO Jacob Dewitte divested approximately 72,960 shares on March 13 at $60 per share, a transaction valued at roughly $4.38 million. CFO Richard Bealmear sold 72,090 shares the same day at an identical price, totaling approximately $4.33 million. Throughout the past 90 days, company insiders have offloaded around 2.07 million shares with a combined value of approximately $170 million. Insiders continue to control 18.9% of the company.

Regulatory Milestones Provide Bright Spots

Not all developments paint a negative picture. Oklo’s Atomic Alchemy subsidiary obtained a DOE Nuclear Safety Design Agreement for its Groves isotopes test reactor. The division also secured an NRC materials and isotope license — marking the first NRC license Oklo has obtained through an acquired subsidiary.

The company’s Aurora reactor earned its initial design approval from the Department of Energy, a crucial milestone for advancing a 1.2-gigawatt power arrangement with Meta, with energy delivery scheduled by 2034.

William Blair reconfirmed an Outperform rating. Cantor Fitzgerald maintained an Overweight designation with a $122 price target. Barclays holds an Overweight rating with an $82 target. Bank of America maintains a Buy rating with a $127 target.

Oklo’s 50-day moving average currently sits at $75.08, while its 200-day moving average rests at $95.27. The company holds a market capitalization of approximately $9.49 billion.

✨ Limited Time Offer